Anti-TNF-alpha therapies in systemic lupus erythematosus
about
Dextran sodium sulphate colitis mouse model: traps and tricksPathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusMacrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus.Daily Moderate Exercise Is Beneficial and Social Stress Is Detrimental to Disease Pathology in Murine Lupus NephritisEnvironmental factors, toxicants and systemic lupus erythematosusSystemic lupus erythematosus complicated by Crohn's disease: a case report and literature review.The presence of high level soluble herpes virus entry mediator in sera of gastric cancer patients.Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing.Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsNormalizing glycosphingolipids restores function in CD4+ T cells from lupus patients.Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.Role of renal transporters and novel regulatory interactions in the TAL that control blood pressure.The potential protective role of hepatitis B virus infection in pristane-induced lupus in mice.Neutrophils Slow Disease Progression in Murine Lupus via Modulation of Autoreactive Germinal Centers.iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling.Anti-IL-7 receptor-α treatment ameliorates newly established Sjögren's-like exocrinopathy in non-obese diabetic mice.
P2860
Q27001084-E2A7485A-46CE-4AA7-91EA-644F4CCAC028Q28088753-F9AFA6F1-6287-47D6-9581-B9DE7DC025B6Q33598493-3E3E41B3-14F0-4568-A558-37DEB3052ED0Q33603442-13E7EFA5-C3B7-4686-9B56-39C2AFBF7D79Q34358712-06B4B14C-ABA2-4D21-A1F8-830C714FBB24Q34502348-89A9F2D6-F7D5-4905-9DAA-3F01C09570A7Q35812556-AB8A8CA7-7143-43EC-A87E-66562B946B28Q35986928-432DAEA0-B128-4B3F-929E-5FBCCF9A0164Q36158922-98EE27B8-4287-46F6-8447-CD2220155057Q37524224-63292A05-C86D-4ED3-ADDF-34F9529A703BQ37561994-A0DB065F-5579-4302-A833-1AFFF830718FQ39227671-5815D1BD-D784-4001-B33E-AD59FF3E09F0Q40695129-77DD2CDF-2B23-454A-B711-FA7FB8881B71Q48325825-446C5CA8-0D78-44ED-90C9-2298F842B493Q49709167-23DCC53F-0434-4A7D-AE23-7270EE0A580EQ52572230-F75E5537-D6B2-48E7-93AB-F79A9A867EE5
P2860
Anti-TNF-alpha therapies in systemic lupus erythematosus
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anti-TNF-alpha therapies in systemic lupus erythematosus
@ast
Anti-TNF-alpha therapies in systemic lupus erythematosus
@en
type
label
Anti-TNF-alpha therapies in systemic lupus erythematosus
@ast
Anti-TNF-alpha therapies in systemic lupus erythematosus
@en
prefLabel
Anti-TNF-alpha therapies in systemic lupus erythematosus
@ast
Anti-TNF-alpha therapies in systemic lupus erythematosus
@en
P2093
P2860
P921
P356
P1476
Anti-TNF-alpha therapies in systemic lupus erythematosus
@en
P2093
Lang-Jing Zhu
Xue-Qing Yu
P2860
P304
P356
10.1155/2010/465898
P577
2010-06-22T00:00:00Z